Phillips D A, Fisher M, Davis M A, Smith T W, Pang R H
Department of Radiology, University of Massachusetts Medical School, Worcester.
Stroke. 1990 Apr;21(4):602-5. doi: 10.1161/01.str.21.4.602.
Fibrinolytic therapy may be effective in the treatment of ischemic stroke, and clinical trials are under way. We evaluated two fibrinolytic agents, an analogue of tissue plasminogen activator (Fb-Fb-CF, the catalytic fragment of the tissue plasminogen activator molecule with a prolonged serum half-life, n = 10) and streptokinase (n = 7), in a rabbit model of embolic stroke. Both agents were given 3 hours after stroke onset, a time relevant to the clinical setting. Fb-Fb-CF was significantly better (p less than 0.04) than saline (n = 7) in restoring blood flow to previously occluded intracranial arteries, but streptokinase was ineffective. Neither fibrinolytic agent was associated with a substantial risk for intracerebral hemorrhagic side effects. Our study demonstrates that Fb-Fb-CF can safely and effectively reperfuse rabbit intracranial arteries 3 hours after occlusion, while streptokinase does not.
纤维蛋白溶解疗法可能对缺血性中风的治疗有效，相关临床试验正在进行中。我们在兔栓塞性中风模型中评估了两种纤维蛋白溶解剂，一种是组织纤溶酶原激活剂类似物（Fb-Fb-CF，组织纤溶酶原激活剂分子的催化片段，血清半衰期延长，n = 10）和链激酶（n = 7）。两种药物均在中风发作后3小时给药，这与临床情况相关。在恢复先前闭塞的颅内动脉血流方面，Fb-Fb-CF明显优于生理盐水（n = 7）（p < 0.04），但链激酶无效。两种纤维蛋白溶解剂均未伴有严重的脑出血副作用风险。我们的研究表明，Fb-Fb-CF可在闭塞3小时后安全有效地使兔颅内动脉再灌注，而链激酶则不能。
